Simple Science

Cutting edge science explained simply

# Physics # Optics # Biological Physics

Advancements in Antibody Screening Technology

High-throughput methods are speeding up antibody discovery for better disease treatments.

Sajjad Abdollahramezani, Darrell Omo-Lamai, Gerlof Bosman, Omid Hemmatyar, Sahil Dagli, Varun Dolia, Kai Chang, Nicholas A. Gusken, Hamish C. Delgado, Geert-Jan Boons, Mark L. Brongersma, Fareeha Safir, Butrus T. Khuri-Yakub, Parivash Moradifar, Jennifer A. Dionne

― 5 min read


Faster Antibody Discovery Faster Antibody Discovery Unveiled effective antibody treatments. New methods expedite the search for
Table of Contents

Once upon a time in the land of science, there was a quest to find better ways to identify Antibodies. Antibodies are like our body's little superheroes, fighting off germs and diseases. Scientists wanted to screen a ton of them quickly to find the most powerful ones. This is where high-throughput antibody screening comes into play, making the process faster and smarter.

What Are Antibodies?

Antibodies are proteins produced by our immune system. They recognize and bind to harmful substances, like viruses and bacteria, effectively marking them for destruction. Think of them as the body’s “Wanted” posters for bad guys. The more diverse the antibodies, the better our immune response.

Why Do We Need High-throughput Screening?

The problem with traditional antibody screening is that it takes ages and can use up a lot of samples. It’s great that scientists can make billions of antibodies using various techniques, but many of these techniques can only analyze a few at a time. Imagine trying to find a needle in a haystack, but you can only check one tiny spot at a time. That’s slow and painful.

What’s The Solution?

Scientists developed a new method called high-throughput nanophotonics- and bioprinter-enabled screening, or HT-NaBS for short. This fancy name means that they are using advanced technology to screen tons of antibodies quickly and efficiently.

How Does HT-NaBS Work?

The magic of HT-NaBS comes from its ability to create tiny sensors on a chip. These sensors are like a bunch of tiny eyes watching for antibodies to show up. Instead of checking one antibody at a time, HT-NaBS can look at hundreds, even thousands, at once.

Step 1: Building the Chip

The chip is designed with tiny sensors, which can be functionalized - that’s a fancy way of saying they can be set up to recognize specific antibodies. The sensors are made from silicon, which helps with light control.

Step 2: Printing Antigens

The scientists use a special printer that can tiny droplets of various antigens (the things antibodies fight against) onto the sensors. It’s a bit like painting dots on a canvas, but the dots are super-duper small.

Step 3: Recognizing Antibodies

Once the antigens are on the sensors, the scientists run a mixture of antibodies over the chip. The sensors detect which antibodies stick to which antigens. If an antibody sticks, that means it recognizes the antigen, and the scientists can learn more about it.

Why Is This Important?

This new method allows scientists to work faster and with less stuff. It helps them find the best antibodies to use as treatments for diseases like COVID-19, influenza, and even some cancers. It’s like discovering a new superhero team, but much more scientific!

Results and Findings

When scientists tried out HT-NaBS, they found it could detect antibodies very quickly, within just 30 minutes. They achieved remarkable precision, even spotting tiny amounts of antibodies.

What About Specificity?

One of the coolest features of HT-NaBS is its high specificity. This means that it can tell apart antibodies that seem similar. In other words, it can recognize the right superhero from a crowd.

The Numbers Game

The scientists also measured how well and how quickly antibodies bind to their targets. They gathered lots of data on how different antibodies behaved, allowing them to see which ones worked best.

The Epitope Binning Adventure

Part of the research involved something called epitope binning. This is a way to see if different antibodies are gunning for the same target. By doing this, scientists can group antibodies together based on which ones are friendly with each other. Nobody wants to duplicate efforts, right?

Conclusions and Future Work

In a nutshell, HT-NaBS has opened doors to faster, more efficient ways to discover powerful antibodies. With more tweaks and improvements, the goal is to create even better screening methods. By working on this technology, scientists hope to speed up the journey from lab to treatment, ultimately helping patients faster.

The Tale Continues

The journey doesn’t stop here. Researchers aim to adapt this technology for other uses, like screening for a variety of biomolecules. The idea is to create a universal system that can tackle different challenges in health and medicine.

A Vision for the Future

Imagine a world where we could quickly find the right antibodies for any disease. With tools like HT-NaBS, that future is becoming a reality, and it’s a very exciting time to be in science!

The End (or just the beginning!)

The work continues as scientists improve upon these methods, making strides in antibody discovery and biotherapeutic development. And who knows? Maybe one day, we’ll look back at these advancements as pivotal moments in medical history.

So there you have it! A complicated topic made simpler, with a dash of humor. Science can be fun, and this journey into the world of antibodies is just getting started!

Original Source

Title: High-throughput antibody screening with high-quality factor nanophotonics and bioprinting

Abstract: Empirical investigation of the quintillion-scale, functionally diverse antibody repertoires that can be generated synthetically or naturally is critical for identifying potential biotherapeutic leads, yet remains burdensome. We present high-throughput nanophotonics- and bioprinter-enabled screening (HT-NaBS), a multiplexed assay for large-scale, sample-efficient, and rapid characterization of antibody libraries. Our platform is built upon independently addressable pixelated nanoantennas exhibiting wavelength-scale mode volumes, high-quality factors (high-Q) exceeding 5000, and pattern densities exceeding one million sensors per square centimeter. Our custom-built acoustic bioprinter enables individual sensor functionalization via the deposition of picoliter droplets from a library of capture antigens at rates up to 25,000 droplets per second. We detect subtle differentiation in the target binding signature through spatially-resolved spectral imaging of hundreds of resonators simultaneously, elucidating antigen-antibody binding kinetic rates, affinity constant, and specificity. We demonstrate HT-NaBS on a panel of antibodies targeting SARS-CoV-2, Influenza A, and Influenza B antigens, with a sub-picomolar limit of detection within 30 minutes. Furthermore, through epitope binning analysis, we demonstrate the competence and diversity of a library of native antibodies targeting functional epitopes on a priority pathogen (H5N1 bird flu) and on glycosylated therapeutic Cetuximab antibodies against epidermal growth factor receptor. With a roadmap to image tens of thousands of sensors simultaneously, this high-throughput, resource-efficient, and label-free platform can rapidly screen for high-affinity and broad epitope coverage, accelerating biotherapeutic discovery and de novo protein design.

Authors: Sajjad Abdollahramezani, Darrell Omo-Lamai, Gerlof Bosman, Omid Hemmatyar, Sahil Dagli, Varun Dolia, Kai Chang, Nicholas A. Gusken, Hamish C. Delgado, Geert-Jan Boons, Mark L. Brongersma, Fareeha Safir, Butrus T. Khuri-Yakub, Parivash Moradifar, Jennifer A. Dionne

Last Update: 2024-11-27 00:00:00

Language: English

Source URL: https://arxiv.org/abs/2411.18557

Source PDF: https://arxiv.org/pdf/2411.18557

Licence: https://creativecommons.org/licenses/by/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to arxiv for use of its open access interoperability.

Similar Articles